{"id":49946,"date":"2025-12-04T19:11:51","date_gmt":"2025-12-04T11:11:51","guid":{"rendered":"https:\/\/flcube.com\/?p=49946"},"modified":"2025-12-04T19:11:52","modified_gmt":"2025-12-04T11:11:52","slug":"duality-db-1324-adc-fda-ind-approval-advances-gsk-partnership","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49946","title":{"rendered":"Duality DB-1324 ADC FDA IND Approval Advances GSK Partnership"},"content":{"rendered":"\n<p><strong>Duality Biotherapeutics, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/9606:HKG\">HKG: 9606<\/a>) announced that its Investigational New Drug (IND) application for <strong>DB-1324<\/strong>, a next\u2011generation Antibody\u2011Drug Conjugate (ADC), has been approved by the <strong>U.S. FDA<\/strong>. Clinical trials for <strong>gastrointestinal tumors<\/strong> will commence in the United States under the company&#8217;s exclusive global ex\u2011Greater China licensing agreement with <strong>GlaxoSmithKline (GSK)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-development-status\">Regulatory Milestone &amp; Development Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Duality Biotherapeutics, Inc. (9606.HK)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>DB-1324<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>FDA IND approval (US)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced\/metastatic gastrointestinal tumors<\/td><\/tr><tr><td><strong>Next Step<\/strong><\/td><td>Clinical trial initiation in US (Q4\u202f2025\/Q1\u202f2026)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-amp-global-development\">Partnership &amp; Global Development<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Partnership Element<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Global Partner<\/strong><\/td><td>GlaxoSmithKline (GSK)<\/td><\/tr><tr><td><strong>Agreement Structure<\/strong><\/td><td>Exclusive global ex\u2011Greater China licensing (signed 2024)<\/td><\/tr><tr><td><strong>Australian Approval<\/strong><\/td><td>HREC approval + TGA CTN clearance (Oct\u202f2025)<\/td><\/tr><tr><td><strong>Development Strategy<\/strong><\/td><td>Coordinated global clinical program across US, Australia, and other markets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-ditac-platform\">Drug Profile &amp; DITAC Platform<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Drug Class<\/strong>: Next\u2011generation ADC<\/li>\n\n\n\n<li><strong>Platform<\/strong>: DualityBio&#8217;s proprietary <strong>DITAC<\/strong> (Duality Immune Toxin Antibody Conjugates) technology<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Targets gastrointestinal tumor antigens with optimized payload delivery<\/li>\n\n\n\n<li><strong>Differentiation<\/strong>: Enhanced stability and tumor\u2011specific release profile vs. first\u2011generation ADCs<\/li>\n\n\n\n<li><strong>Pipeline Position<\/strong>: Lead oncology asset in DualityBio&#8217;s ADC franchise<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-strategic-outlook\">Market Context &amp; Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>GI Tumor Burden<\/strong>: Over <strong>2 million<\/strong> new gastrointestinal cancer cases annually in US\/EU\/Japan combined<\/li>\n\n\n\n<li><strong>ADC Market Growth<\/strong>: Global ADC market projected to reach <strong>$15\u202fbillion<\/strong> by 2030, with GI tumors as emerging indication<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong>: DB-1324 enters competitive but underserved GI oncology space<\/li>\n\n\n\n<li><strong>First\u2011Mover Advantage<\/strong>: FDA IND clearance accelerates timeline vs. other pipeline ADCs targeting GI tumors<\/li>\n\n\n\n<li><strong>Revenue Upside<\/strong>: GSK partnership provides milestone payments and tiered royalties, reducing DualityBio&#8217;s R&amp;D burden<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding DB-1324 development timelines, clinical outcomes, and partnership execution. Actual results may differ due to clinical, regulatory, and competitive uncertainties.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Duality Biotherapeutics, Inc. (HKG: 9606) announced that its Investigational New Drug (IND) application for DB-1324,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49949,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,16,62,3795,278,184,3974],"class_list":["post-49946","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-cancer","tag-clinical-trial-approval-initiation","tag-duality-biotherapeutics","tag-glaxosmithkline","tag-gsk","tag-hkg-9606"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Duality DB-1324 ADC FDA IND Approval Advances GSK Partnership - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Duality Biotherapeutics, Inc. (HKG: 9606) announced that its Investigational New Drug (IND) application for DB-1324, a next\u2011generation Antibody\u2011Drug Conjugate (ADC), has been approved by the U.S. FDA. Clinical trials for gastrointestinal tumors will commence in the United States under the company&#039;s exclusive global ex\u2011Greater China licensing agreement with GlaxoSmithKline (GSK).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49946\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Duality DB-1324 ADC FDA IND Approval Advances GSK Partnership\" \/>\n<meta property=\"og:description\" content=\"Duality Biotherapeutics, Inc. (HKG: 9606) announced that its Investigational New Drug (IND) application for DB-1324, a next\u2011generation Antibody\u2011Drug Conjugate (ADC), has been approved by the U.S. FDA. Clinical trials for gastrointestinal tumors will commence in the United States under the company&#039;s exclusive global ex\u2011Greater China licensing agreement with GlaxoSmithKline (GSK).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49946\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-04T11:11:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-04T11:11:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0404.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49946#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49946\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Duality DB-1324 ADC FDA IND Approval Advances GSK Partnership\",\"datePublished\":\"2025-12-04T11:11:51+00:00\",\"dateModified\":\"2025-12-04T11:11:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49946\"},\"wordCount\":301,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49946#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0404.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Duality Biotherapeutics\",\"GlaxoSmithKline\",\"GSK\",\"HKG: 9606\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49946#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49946\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49946\",\"name\":\"Duality DB-1324 ADC FDA IND Approval Advances GSK Partnership - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49946#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49946#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0404.webp\",\"datePublished\":\"2025-12-04T11:11:51+00:00\",\"dateModified\":\"2025-12-04T11:11:52+00:00\",\"description\":\"Duality Biotherapeutics, Inc. (HKG: 9606) announced that its Investigational New Drug (IND) application for DB-1324, a next\u2011generation Antibody\u2011Drug Conjugate (ADC), has been approved by the U.S. FDA. Clinical trials for gastrointestinal tumors will commence in the United States under the company's exclusive global ex\u2011Greater China licensing agreement with GlaxoSmithKline (GSK).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49946#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49946\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49946#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0404.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/0404.webp\",\"width\":1080,\"height\":608,\"caption\":\"Duality DB-1324 ADC FDA IND Approval Advances GSK Partnership\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49946#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Duality DB-1324 ADC FDA IND Approval Advances GSK Partnership\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Duality DB-1324 ADC FDA IND Approval Advances GSK Partnership - Insight, China&#039;s Pharmaceutical Industry","description":"Duality Biotherapeutics, Inc. (HKG: 9606) announced that its Investigational New Drug (IND) application for DB-1324, a next\u2011generation Antibody\u2011Drug Conjugate (ADC), has been approved by the U.S. FDA. Clinical trials for gastrointestinal tumors will commence in the United States under the company's exclusive global ex\u2011Greater China licensing agreement with GlaxoSmithKline (GSK).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49946","og_locale":"en_US","og_type":"article","og_title":"Duality DB-1324 ADC FDA IND Approval Advances GSK Partnership","og_description":"Duality Biotherapeutics, Inc. (HKG: 9606) announced that its Investigational New Drug (IND) application for DB-1324, a next\u2011generation Antibody\u2011Drug Conjugate (ADC), has been approved by the U.S. FDA. Clinical trials for gastrointestinal tumors will commence in the United States under the company's exclusive global ex\u2011Greater China licensing agreement with GlaxoSmithKline (GSK).","og_url":"https:\/\/flcube.com\/?p=49946","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-04T11:11:51+00:00","article_modified_time":"2025-12-04T11:11:52+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0404.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49946#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49946"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Duality DB-1324 ADC FDA IND Approval Advances GSK Partnership","datePublished":"2025-12-04T11:11:51+00:00","dateModified":"2025-12-04T11:11:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49946"},"wordCount":301,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49946#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0404.webp","keywords":["ADC \/ XDC","Cancer","Clinical trial approval \/ initiation","Duality Biotherapeutics","GlaxoSmithKline","GSK","HKG: 9606"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49946#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49946","url":"https:\/\/flcube.com\/?p=49946","name":"Duality DB-1324 ADC FDA IND Approval Advances GSK Partnership - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49946#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49946#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0404.webp","datePublished":"2025-12-04T11:11:51+00:00","dateModified":"2025-12-04T11:11:52+00:00","description":"Duality Biotherapeutics, Inc. (HKG: 9606) announced that its Investigational New Drug (IND) application for DB-1324, a next\u2011generation Antibody\u2011Drug Conjugate (ADC), has been approved by the U.S. FDA. Clinical trials for gastrointestinal tumors will commence in the United States under the company's exclusive global ex\u2011Greater China licensing agreement with GlaxoSmithKline (GSK).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49946#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49946"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49946#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0404.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0404.webp","width":1080,"height":608,"caption":"Duality DB-1324 ADC FDA IND Approval Advances GSK Partnership"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49946#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Duality DB-1324 ADC FDA IND Approval Advances GSK Partnership"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/0404.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49946"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49946\/revisions"}],"predecessor-version":[{"id":49950,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49946\/revisions\/49950"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49949"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49946"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49946"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}